---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-033402"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:57:24.594635+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx plans new independent director in H2 2025; Whetstone withdraws nomination notice

## Summary
- Plans to add a new independent director in H2 2025 as part of ongoing board refreshment.
- Whetstone Capital Advisors withdrew its March 6 director nomination notice after constructive engagement.
- Current board has five members; three new directors added since 2020 including Klema (2024) and Wasson (2020).
- Chairperson Lynn Vos cites progress under CEO Steve Silvestro and commitment to recruiting qualified directors.

## SEC filing metadata
- accession: 0001213900-25-033402
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390025033402/0001213900-25-033402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390025033402/ea0238866-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-033402
- JSON: https://secwatch.observer/filing/0001213900-25-033402.json
- Plain text: https://secwatch.observer/filing/0001213900-25-033402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.